Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937866 · ClinicalTrials.gov registry record · Phase 1
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
A Phase 1 study of Germ Cell Tumor, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06937866 is a Phase 1 study of Germ Cell Tumor that is actively recruiting participants, run by Indiana University. The registered enrollment target is 38 participants, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06937866, a Phase 1 study of Germ Cell Tumor, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
Conditions Studied
Interventions
- DRUG Zanzalintinib
- DRUG Etoposide Capsule
Study Locations (1)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2031-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06937866
The ClinicalTrials.gov registry entry for NCT06937866 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (89% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Germ Cell Tumor appearing as the primary indexed condition, and to 2 interventions - of which Zanzalintinib is the first listed.
NCT06937866 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06937866 about?
NCT06937866 is a clinical study titled "Maintenance Zanzalintinib With Etoposide After HDCT in GCT". This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
What is the current status of trial NCT06937866?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2025-11-12. Estimated completion is 2031-09.
What conditions does trial NCT06937866 study?
This clinical trial studies the following conditions: Germ Cell Tumor.
What interventions are being tested in trial NCT06937866?
The interventions under investigation include: Zanzalintinib (DRUG), Etoposide Capsule (DRUG).
Who is sponsoring clinical trial NCT06937866?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937866 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
-
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.